- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01224808
Extension Study of Biostate in Subjects With Von Willebrand Disease
October 2, 2017 updated by: CSL Behring
An Open-Label, Multi-Centre Extension Study to Assess the Efficacy and Safety of Biostate® in Paediatric, Adolescent, and Adult Subjects With Von Willebrand Disease Who Completed Clinical Studies CSLCT-BIO-08-52 or CSLCTBIO-08-54
The aim of the Von Willebrand Disease (VWD) therapy is to treat and prevent bleeding episodes due to abnormal platelet adhesion and abnormal blood coagulation as a result of low or abnormal Von Willebrand Factor (VWF) and/or Factor VIII (FVIII) levels.
The long-term efficacy and safety of a VWF/FVIII concentrate, Biostate, will be investigated in children, adolescents, and adults with VWD in whom treatment with a VWF product is required for prophylactic therapy, haemostatic control during surgery, or control of a non-surgical, spontaneous, or traumatic bleeding event.
Study Overview
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sofia, Bulgaria
- Study Site
-
-
-
-
-
Bremen, Germany
- Study Site
-
-
-
-
-
Warsaw, Poland
- Study Site
-
Wroclaw, Poland
- Study Site
-
-
-
-
-
Barnaul, Russian Federation
- Study Site
-
-
-
-
-
Lviv, Ukraine
- Study Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have completed Study CSLCT-BIO-08-52 (Assessment of Efficacy and Safety of Biostate in Paediatric Subjects with Von Willebrand Disease) or Study CSLCT-BIO-08-54 (Assessment of Efficacy and Safety of Biostate in Adolescent or Adult Subjects with Von Willebrand Disease).
- The subject and/or his/her legal guardian understand(s) the nature of the study and has/have given written informed consent to participate in the study and is/are willing to comply with the protocol.
Exclusion Criteria:
- Early discontinuation of a subject from the main studies CSLCT-BIO-08-52 or CSLCT-BIO-08-54.
- Mental condition rendering the subject (or the subject's legal guardian) unable to understand the nature, scope and possible consequences of the study.
- Any condition that is likely to interfere with evaluation of the IMP or satisfactory conduct of the study.
- Are not willing and/or not able to comply with the study requirements.
- Employee at the study site, or spouse/partner or relative of the Investigator or Subinvestigators.
- Female subjects of childbearing potential either not using, or not willing to use, a medically reliable method of contraception for the entire duration of the study, or not sexually abstinent for the entire duration of the study, or not surgically sterile.
- Intention to become pregnant during the course of the study.
- Pregnancy, or nursing mother.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
|
Single bolus doses, administered intravenously.
Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Haemostatic efficacy
Time Frame: Up to 32 months
|
Up to 32 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Development of FVIII inhibitors
Time Frame: Up to 32 months
|
Up to 32 months
|
Development of VWF inhibitors
Time Frame: Up to 32 months
|
Up to 32 months
|
Frequency of Adverse events (AEs) per subject
Time Frame: 32 months
|
32 months
|
Severity of AEs per subject
Time Frame: 32 months
|
32 months
|
Severity of AEs per infusion
Time Frame: 32 months
|
32 months
|
Causality of AEs per subject
Time Frame: 32 months
|
32 months
|
Causality of AEs per infusion
Time Frame: 32 months
|
32 months
|
Frequency of Adverse events (AEs) per infusion
Time Frame: 32 months
|
32 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Primary Completion (Actual)
March 1, 2014
Study Completion (Actual)
March 1, 2014
Study Registration Dates
First Submitted
June 8, 2010
First Submitted That Met QC Criteria
October 19, 2010
First Posted (Estimate)
October 20, 2010
Study Record Updates
Last Update Posted (Actual)
October 3, 2017
Last Update Submitted That Met QC Criteria
October 2, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSLCT-BIO-09-64
- 2009-017301-11 (EudraCT Number)
- 1498 (CSL Behring)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Von Willebrand Disease
-
Baxalta now part of ShireCompletedVon Willebrand DiseaseUnited States, Germany, United Kingdom, Italy, Austria, Canada
-
Fondazione Angelo Bianchi BonomiSintesi Research SrlActive, not recruitingType 3 Von Willebrand's DiseaseFinland, France, Germany, Hungary, Iran, Islamic Republic of, Italy, Netherlands, Spain, Sweden, United Kingdom
-
University Hospital, CaenRecruitingVon Willebrand Disease, Type 2BFrance
-
Archemix Corp.Withdrawn
-
TakedaAvailableVon Willebrand Disease (VWD)
-
Archemix Corp.CompletedPurpura, Thrombotic Thrombocytopenic | Von Willebrand Disease Type-2bAustria
-
St. James's Hospital, IrelandUnknown
-
Tirol Kiniken GmbHLFB BIOMEDICAMENTSUnknown
-
TakedaNot yet recruitingVon Willebrand Disease (VWD)
-
Baxalta now part of ShireTakeda Development Center Americas, Inc.RecruitingVon Willebrand Disease (VWD)United States, Italy, Spain, Netherlands, Turkey, France, Austria, Germany, Russian Federation
Clinical Trials on Biostate
-
CSL BehringParexelCompletedVon Willebrand DiseaseUkraine, Lebanon, Germany, Belarus, Georgia, Guatemala
-
CSL BehringTerminatedHemophilia ARussian Federation, Germany, Italy, Austria, Greece
-
CSL BehringParexelCompletedHemophilia ABulgaria, Poland, Russian Federation, Macedonia, The Former Yugoslav Republic of
-
CSL BehringParexelCompletedHemophilia AUkraine, Lebanon, Belarus, Georgia, Guatemala, Mexico
-
CSL BehringCompletedVon Willebrand DiseaseFrance
-
CSL BehringParexelCompletedVon Willebrand DiseaseBulgaria, Poland, Russian Federation, Ukraine